Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low-dose chidamide maintenance therapy following allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia or lymphoma: A phase 2, open-label, multicenter, single-arm trial

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYi YuCentral South UniversityWCWeihao ChenHunan Institute of Science and TechnologyJSJimin ShiZhejiang Chinese Medical University

Discussion

Loading...

Member takes

Implication

Phase 2 trial shows chidamide maintenance improves relapse incidence in T-cell malignancies, suggesting safer post-transplant care.

Key Points

  • This trial aimed to assess the efficacy and safety of chidamide as maintenance therapy post-allo-HSCT in patients with T-ALL/TCL.
  • Phase II, open-label, single-arm clinical trial
  • Patients aged 14-70 with confirmed T-ALL or T-cell lymphomas
  • Chidamide initiated at 10 mg biw post-transplant, continued for up to 2 years
  • Primary endpoint: 2-year relapse-free survival
  • 44 patients received chidamide maintenance therapy
  • 2-year cumulative incidence of relapse was 9.6%
  • Common adverse events included neutropenia and anemia, mostly grade 1-2

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfb5https://doi.org/10.1182/blood-2025-169
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of chidamide for maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with T-ALL/T-LBL2026
  2. 2Effectiveness and safety profile of chidamide as maintenance therapy for peripheral T-cell lymphoma: a multicenter real-world study2025
  3. 3A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL2024 · 4 citations
  4. 4MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia2026
  5. 5Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation2024